Visionary Holdings announces strategic alliance with Yike Regenerative Medicine

Visionary Holdings (GV) entered into a strategic partnership with Jiangsu Yike Regenerative Medicine. The two parties will combine their respective strengths to collaborate on research, development, and commercialization in the fields of cellular rejuvenation and aesthetic treatment. Under the partnership framework, Yike will continue to lead the project and fund the research and development. Upon completion, Yike will file the results and secure the related intellectual property. GV will then evaluate the outcomes and, based on the market potential, may acquire or license the rights through purchase or leasing agreements. Consideration will be paid in cash or GV shares, with detailed valuation and payment terms to be determined in follow-up agreements. GV and Yike will collaborate in the following core areas: Cell Activation and Telomerase Homeostasis: building on Yike’s proprietary Cell-Activating Complex and its expertise in telomere detection and intervention to develop a new generation of advanced anti-aging product lines. Smart Delivery and Personalized Solutions: leveraging Yike’s Nano-Delivery ultra-permeable liposomal technology to enhance transdermal absorption of active ingredients, integrated with its AI-based Aging Assessment Model to provide consumers with precise, personalized rejuvenation solutions. Stem Cell and Immune Cell Applications: utilizing Yike’s experience in stem cell and immune cell therapies and its cGMP-certified laboratories to explore innovative applications of cell therapies in aesthetics and healthcare.